1. Lab Supplies
Source Explicitly mentioned as a primary driver of cost of sales increase in Q2 2026. Includes reagents, consumables, and other materials used in diagnostic tests.
Confidence: medium
CSTL
T13.0% portfolioCastle Biosciences, Inc.
Genomics '25: Molecular Diagnostics & Clinical GenomicsMedTech Long '26: Diagnostics & Early Detection
Loading chart…
OverviewCastle Biosciences, Inc. is a diagnostics firm offering tests for dermatological cancers like melanoma (DecisionDx-Melanoma), gastrointestinal conditions (Tissu
Castle Biosciences, Inc. is a diagnostics firm offering tests for dermatological cancers like melanoma (DecisionDx-Melanoma), gastrointestinal conditions (TissueCypher), and atopic dermatitis (AdvanceAD-Tx). These tests aid risk assessment and treatment selection. Selling to healthcare providers, the company reported strong Q2 2026 results, raising full-year revenue guidance to $365-$375 million and expecting positive adjusted EBITDA for 2026.
Key Inputs And Sourcing
2. Personnel Costs (Lab Operations)
Source Explicitly mentioned as a primary driver of cost of sales increase in Q2 2026, reflecting higher headcount and wage adjustments for lab personnel.
Confidence: medium
3. Lab Services Costs
Source Explicitly mentioned as a primary driver of cost of sales increase in Q2 2026, reflecting higher test report volumes and potentially outsourced specialized services.
Confidence: medium
Industry Publications
- GenomeWeb (genomeweb.com) — Comprehensive coverage of genomics, molecular diagnostics, liquid biopsy, and precision medicine, including business, research, and regulatory news, highly relevant for CSTL's diagnostic tests.
- Fierce Biotech (fiercebiotech.com) — Covers biotech industry news, clinical trials, FDA approvals, M&A, and company strategies relevant to the broader diagnostics and life sciences sector in which CSTL operates.
- Endpoints News (endpts.com) — Focuses on pharmaceutical and biotech news, including clinical development, regulatory affairs, and business strategies, which are critical for monitoring CSTL's pipeline and market access.
- STAT News (statnews.com) — Provides in-depth reporting on health, medicine, and life sciences, including policy, research, and industry trends that could impact CSTL's diagnostic offerings and reimbursement landscape.
- BioSpace (biospace.com) — Offers news, jobs, and insights for the life sciences industry, covering biotech, pharma, and diagnostics, providing a broad view of the competitive and innovation environment for CSTL.
Economic Data Watch
1. FRED (Federal Reserve Economic Data) — National Health Expenditure Accounts
Metric/field Total Health Expenditures (TEXPAM)
Cadence quarterly
Why it matters Overall healthcare spending indicates the market size and health for diagnostic services, directly impacting CSTL's addressable market.
Signal to watch Increasing trend suggests a supportive environment for healthcare companies and potential for higher test volumes.
Confidence: high
2. FRED (Federal Reserve Economic Data) — Personal Consumption Expenditures
Metric/field Personal Consumption Expenditures (PCE)
Cadence monthly
Why it matters Reflects general economic health and consumer spending capacity, indirectly impacting elective healthcare services and out-of-pocket expenses for patients.
Signal to watch Sustained growth indicates a healthy economic backdrop, potentially leading to more patient visits and test orders.
Confidence: medium
3. FRED (Federal Reserve Economic Data) — Federal Funds Rate
Metric/field Federal Funds Effective Rate (FEDFUNDS)
Cadence daily
Why it matters Influences the company's interest income on its substantial cash reserves and potential borrowing costs for future investments or acquisitions.
Signal to watch Stable or declining rates are generally favorable for growth companies, supporting investment and reducing financing costs.
Confidence: high
4. FRED (Federal Reserve Economic Data) — Consumer Price Index
Metric/field Consumer Price Index for All Urban Consumers: All Items in U.S. City Average, Seasonally Adjusted (CPIAUCSL)
Cadence monthly
Why it matters Impacts operating costs such as lab supplies, personnel expenses, and general administrative overhead, affecting gross margins.
Signal to watch Moderate and stable inflation is manageable; high or accelerating inflation can compress margins if not offset by pricing power.
Confidence: high
5. FRED (Federal Reserve Economic Data) — Labor Force Statistics
Metric/field Unemployment Rate (UNRATE)
Cadence monthly
Why it matters A lower unemployment rate typically correlates with higher rates of employer-sponsored health insurance, which is crucial for commercial reimbursement for CSTL's tests.
Signal to watch Declining or consistently low unemployment rates are positive for a favorable commercial payer mix and stable collections.
Confidence: high
Free Alt Data Watch
1. Google Trends — Search Interest
Metric/field "DecisionDx-Melanoma" (search term volume)
Cadence weekly
Why it matters Indicates public and potentially physician interest and awareness in the company's flagship dermatological cancer diagnostic product.
Signal to watch Increasing or stable search interest suggests sustained market relevance and potential for continued test report volumes.
Confidence: high
2. Google Trends — Search Interest
Metric/field "TissueCypher" (search term volume)
Cadence weekly
Why it matters Reflects growing awareness and potential demand for the high-growth gastroenterology test, which is a key revenue driver.
Signal to watch Sustained upward trend in search interest supports continued volume growth and market penetration.
Confidence: high
3. Google Trends — Search Interest
Metric/field "AdvanceAD-Tx" (search term volume)
Cadence weekly
Why it matters Monitors early adoption and increasing interest in the new atopic dermatitis test, especially as it moves towards a full commercial launch and reimbursement clarity.
Signal to watch Significant and sustained increase in search interest indicates successful market penetration efforts and growing physician/patient engagement.
Confidence: high
4. ClinicalTrials.gov — Study Database
Metric/field "Castle Biosciences" (number of active studies, results posted)
Cadence quarterly
Why it matters Tracks ongoing R&D, evidence generation, and pipeline advancements, which are crucial for future growth, regulatory approvals, and reimbursement support.
Signal to watch Consistent new studies or positive results indicate a robust pipeline and a strong evidence-based strategy.
Confidence: medium
5. CMS.gov (Medicare Coverage Database) — Local Coverage Determinations (LCDs)
Metric/field "DecisionDx-SCC" (LCD status, publication date of draft/final)
Cadence event_driven
Why it matters Directly impacts reimbursement and market access for DecisionDx-SCC, a test that previously lost coverage and is undergoing reconsideration.
Signal to watch Publication of a favorable draft LCD in H2 2026 would be a strong positive signal for future revenue contribution.
Confidence: high
Paid Alt Data Watch
1. Claims Data Provider (e.g., IQVIA, Symphony Health) — Medical Claims Data
Metric/field DecisionDx-Melanoma test volume (by CPT code)
Cadence monthly
Why it matters Provides granular, independent data on actual test utilization and market share for the flagship product, complementing company-reported figures.
Signal to watch Consistent or accelerating volume growth, especially relative to competitors, is a bullish indicator of market strength.
Confidence: high
2. Claims Data Provider (e.g., IQVIA, Symphony Health) — Medical Claims Data
Metric/field TissueCypher test volume (by CPT code)
Cadence monthly
Why it matters Monitors the actual adoption and growth trajectory of the high-growth gastroenterology test, providing an independent verification of company claims.
Signal to watch Sustained high year-over-year growth in test volumes indicates successful market penetration and continued demand.
Confidence: high
3. Claims Data Provider (e.g., IQVIA, Symphony Health) — Medical Claims Data
Metric/field AdvanceAD-Tx average reimbursement rate (by CPT code)
Cadence monthly
Why it matters Crucial for understanding the actual realized pricing and reimbursement landscape for the new AdvanceAD-Tx test as it scales commercially.
Signal to watch Average reimbursement rates consistent with or above the expected $3,675 crosswalk rate are positive for revenue generation.
Confidence: high
4. Job Postings Data Provider (e.g., Revelio Labs, LinkUp) — Company Job Postings
Metric/field Castle Biosciences total active job postings (sales & R&D roles)
Cadence weekly
Why it matters Indicates the company's investment in commercial expansion and pipeline development, aligning with stated growth strategies and future potential.
Signal to watch Increasing postings, particularly in sales and R&D, suggest aggressive growth initiatives and confidence in market opportunities.
Confidence: medium
5. Physician Survey Data Provider (e.g., Spherix Global Insights, InCrowd) — Dermatologist/Gastroenterologist Surveys
Metric/field AdvanceAD-Tx physician adoption rate (percentage of surveyed dermatologists who have ordered)
Cadence quarterly
Why it matters Provides direct insights into physician awareness, intent to use, and actual adoption of new tests like AdvanceAD-Tx, which is critical for its commercial success.
Signal to watch Rising adoption rates among target specialists indicate successful commercialization and growing clinical utility.
Confidence: medium
Search Keywords Brand Product
- DecisionDx-Melanoma
- TissueCypher
- AdvanceAD-Tx
- DecisionDx-SCC
- IDgenetix
- Esopredict
- DETECT-AD study
- molecular diagnostics
- gene expression profile
- dermatological cancers
- melanoma testing
- squamous cell carcinoma testing
- Barrett's esophagus
- atopic dermatitis treatment selection
- prognostic testing
- diagnostic testing
- gastroenterology diagnostics
Search Keywords Event Phrases
- Castle Biosciences earnings
- Q2 2026 results
- AdvanceAD-Tx crosswalk vote
Search Keywords Policy Regulatory
- Medicare coverage
- CLFS rate schedules
- MolDx coverage
- Novitas LCD
- FDA breakthrough device designation
- What They Do (Plain English & Analogies)
- Castle Biosciences acts like a specialized detective agency for certain skin and gut conditions. Instead of looking for clues at a crime scene, they analyze a patient's genes to figure out how aggressive a disease might be or which treatment would work best. For example, if someone has skin cancer (melanoma), they can run a test on the tumor to predict if it's likely to spread, helping doctors decide if more intense monitoring or treatment is needed. They also have tests for a gut condition called Barrett's esophagus to assess the risk of it progressing to cancer, and a new test for a severe skin condition (atopic dermatitis) to help doctors pick the right medication. They provide these advanced genetic tests to doctors to help them make more personalized and informed decisions for their patients.
- Very Brief History
- Castle Biosciences, Inc. was founded in September 2007 and is headquartered in Friendswood, Texas. The company initially built its growth around melanoma decision-support testing with its flagship product DecisionDx-Melanoma. It expanded into gastroenterology with the 2021 acquisition of Cernostics assets and into mental-health pharmacogenomics with the 2022 acquisition of AltheaDx. The company went public in 2019.
- "Street Stereotype"
- Castle Biosciences is generally perceived by investors and analysts as an "exceptional mid-cap momentum" company within the Diagnostics & Early Detection sector. The market views it as a growth story, particularly driven by the high-volume utilization of its TissueCypher test and solid margin improvements. There's an expectation of continued expansion beyond its core dermatological cancer diagnostics into new areas like gastroenterology and inflammatory skin conditions.
- Subsidiaries On Linked In*
- {"subsidiaries":[]}
- Customer Sectors & Example Clients
- Castle Biosciences' customers are primarily in the healthcare sector, specifically medical professionals and institutions involved in dermatology, ophthalmology, and gastroenterology. Example clients would include dermatologists, surgical oncologists (for melanoma and SCC), gastroenterologists, pathologists, and hospitals and clinics that treat patients with skin cancers, uveal melanoma, Barrett's esophagus, and atopic dermatitis.
- New Customers / Segments They'Re Targeting
- Castle Biosciences is actively targeting patients aged 12 and up with moderate to severe atopic dermatitis, along with their dermatological clinicians, through its AdvanceAD-Tx test. The company is also exploring new segments within atopic dermatitis management, such as preventative flare detection and personalized medication tapering, through initiatives like the DETECT-AD study with SciBase, aiming to empower patients with tools for better disease control.
- Sales Geographies And Expansion Plans
- Castle Biosciences primarily sells its products in the United States. The company's headquarters are in Friendswood, Texas, and it operates laboratory facilities in Phoenix, Arizona, and Pittsburgh, Pennsylvania. The recent recognition of AdvanceAD-Tx and its crosswalk rate will help set conversations with commercial payers, supporting a full launch in the future within the U.S. market. There is no explicit mention in the provided information about plans to expand sales into new international geographies.
- How Key Themes May Help/Hurt
- Castle Biosciences is directly positioned within the "Diagnostics & Early Detection" theme. The accelerating technological advancements in genomics and multiomics directly benefit the company, as its core business revolves around advanced multi-gene expression profile (GEP) tests for various conditions. The increasing prevalence of chronic diseases, particularly cancers and inflammatory conditions like atopic dermatitis, creates a growing demand for their diagnostic solutions, expanding their addressable market. Favorable regulatory developments, such as the strong crosswalk rate for AdvanceAD-Tx and the potential for regaining Medicare coverage for DecisionDx-SCC, are critical for enhancing market access and accelerating adoption of their tests. However, the company can be hurt by persistent reimbursement pressures and evolving payer policies, as evidenced by past challenges with DecisionDx-SCC coverage. Significant regulatory hurdles and the need for extensive evidence generation for new tests can also impede timely rollout and broad adoption. Additionally, intensifying competition in the diagnostics space could lead to pricing pressures and increased commercialization costs.
3 Main Long-Term Bull Details
- Castle Biosciences delivered exceptional Q2 2026 financial results, with total revenue growing 20% year-over-year to $103.5 million, and core revenue drivers (excluding DecisionDx-SCC and IDgenetix) surging 40%. This strong performance, particularly TissueCypher's 63% volume growth, led to a raised 2026 revenue guidance of $365 million to $375 million, signaling robust market penetration and execution.
- The AdvanceAD-Tx test for atopic dermatitis is gaining significant traction, with over 1,000 orders in Q2 2026 and recognition via the Genomics Innovation Award. A new clinical utility study demonstrated 97.8% of patients initiated molecularly concordant systemic therapy post-testing. The unanimous panel vote for a $3,675 crosswalk rate provides a strong reimbursement benchmark, positioning AdvanceAD-Tx as a key midterm growth driver.
- Castle Biosciences demonstrates a clear path to profitability, expecting positive adjusted EBITDA for Q3, Q4, and the full year 2026, as well as for 2027. This financial discipline, coupled with a robust balance sheet of $266.8 million in cash and marketable securities, provides significant flexibility to fund ongoing growth initiatives and strategic pipeline advancements.
3 Main Long-Term Bear Details
- Despite a favorable crosswalk rate for AdvanceAD-Tx, final reimbursement clarity from commercial payers is contingent on the preliminary draft 2026 CLFS rate schedules in late September. Furthermore, regaining Medicare coverage for DecisionDx-SCC is still projected to be approximately a year after a positive draft LCD, which itself is only anticipated in the second half of 2026.
- The company continues to experience adjusted gross margin compression, with Q2 2026 adjusted gross margin at 76.3% compared to 79.5% in Q2 2025. This decline is primarily driven by increased costs for lab supplies, personnel, and lab services, reflecting investments in capacity and higher test volumes.
- DecisionDx-Melanoma experienced moderate sequential volume growth in Q2 2026, below typical seasonality, partly due to the commercial team adapting to support three products. Additionally, management acknowledges that TissueCypher will increasingly face "headwinds of big numbers," implying that converting remaining physicians will require more effort and potentially higher sales and marketing efficiency to maintain current growth rates.
- Competitors And Differentiation
- Castle Biosciences operates in the molecular diagnostics space for dermatological cancers (melanoma, squamous cell carcinoma), uveal melanoma, Barrett's esophagus, and atopic dermatitis. While specific competitors are not named in the provided text, the company differentiates itself through its proprietary multi-gene expression profile (GEP) tests, such as DecisionDx-Melanoma, which has demonstrated superior performance in identifying patient risk. Their strategy involves generating robust clinical evidence to support the utility and actionability of their tests, providing personalized insights to guide patient care decisions, and expanding into new therapeutic areas like atopic dermatitis with tests like AdvanceAD-Tx.
- Recent Performance & What The Market'S Focused On
- Castle Biosciences recently reported strong Q2 2026 results, with revenue of $103.5 million, a 20% year-over-year increase, and core test volumes up 32%. This performance, particularly TissueCypher's 63% year-over-year volume growth, led the company to raise its full-year 2026 revenue guidance to $365 million to $375 million. The company also anticipates achieving positive adjusted EBITDA for the remainder of 2026 and for the full year 2027. The market is focused on the sustainability of this growth, particularly for TissueCypher as it faces "headwinds of big numbers," and the successful commercialization and reimbursement clarity for the new AdvanceAD-Tx test following its favorable crosswalk rate. Additionally, the market is tracking progress on regaining Medicare coverage for DecisionDx-SCC and the impact of sales force adjustments on DecisionDx-Melanoma's growth.
- Revenue Segments And Estimated Mix
- DecisionDx-Melanoma — Mix: Significant, core revenue driver; Source: Q2 2026 transcript, 10,280 test reports in Q2 2026; Trend: 3% growth compared to Q2 2025; mid- to high single-digit volume growth expected for full year 2026
- TissueCypher — Mix: Significant, core revenue driver; Source: Q2 2026 transcript, 14,988 test reports in Q2 2026; Trend: 63% growth compared to Q2 2025; 50% to 52% volume growth expected for full year 2026
- AdvanceAD-Tx — Mix: Emerging, midterm revenue driver; Source: Q2 2026 transcript, more than 1,000 orders in Q2 2026; Trend: Expected to be a midterm revenue driver for 2027 and 2028, with reimbursement clarity anticipated following CLFS rate schedules
- DecisionDx-SCC — Mix: Smaller, excluded from core growth; Source: Q2 2026 transcript, excluded from core revenue growth calculation; Trend: Volume pickup in Q2 2026 due to existing clinical value and some promotional time; awaiting draft LCD in H2 2026
- IDgenetix — Mix: Smaller, excluded from core growth; Source: Q2 2026 transcript, excluded from core revenue growth calculation for both 2026 and 2025; Trend: Excluded from core revenue growth calculation for both 2026 and 2025
- Product Brands
- DecisionDx-Melanoma
- DecisionDx-UM
- DecisionDx-SCC
- DecisionDx DiffDx-Melanoma
- myPath Melanoma
- TissueCypher
- AdvanceAD-Tx
- IDgenetix
- DecisionDx-CMSeq
- i31-SLNB
- i31-ROR
- Esopredict
- DecisionDx-PRAME
- DecisionDx-UMSeq
- Previse GI
Bull / Bear DetailsCastle Biosciences, a commercial-stage diagnostics firm, is demonstrating exceptional execution and accelerating growth in its core DecisionDx-Melanoma and Tiss
Thesis
Castle Biosciences, a commercial-stage diagnostics firm, is demonstrating exceptional execution and accelerating growth in its core DecisionDx-Melanoma and TissueCypher franchises, leading to a significantly raised 2026 revenue outlook and anticipated positive adjusted EBITDA. Its AdvanceAD-Tx for atopic dermatitis shows promising early adoption and a strong reimbursement signal. While navigating ongoing reimbursement complexities for SCC, robust clinical evidence and pipeline expansion underpin its compelling long-term growth trajectory. (Updated: 2026-08-05)
Bull case
Castle Biosciences delivered exceptional Q2 2026 financial results, with total revenue growing 20% year-over-year to $103.5 million, and core revenue drivers (excluding DecisionDx-SCC and IDgenetix) surging 40%. This strong performance, particularly TissueCypher's 63% volume growth, led to a raised 2026 revenue guidance of $365 million to $375 million, signaling robust market penetration and execution.
The AdvanceAD-Tx test for atopic dermatitis is gaining significant traction, with over 1,000 orders in Q2 2026 and recognition via the Genomics Innovation Award. A new clinical utility study demonstrated 97.8% of patients initiated molecularly concordant systemic therapy post-testing. The unanimous panel vote for a $3,675 crosswalk rate provides a strong reimbursement benchmark, positioning AdvanceAD-Tx as a key midterm growth driver.
Castle Biosciences demonstrates a clear path to profitability, expecting positive adjusted EBITDA for Q3, Q4, and the full year 2026, as well as for 2027. This financial discipline, coupled with a robust balance sheet of $266.8 million in cash and marketable securities, provides significant flexibility to fund ongoing growth initiatives and strategic pipeline advancements.
Bear case
Despite a favorable crosswalk rate for AdvanceAD-Tx, final reimbursement clarity from commercial payers is contingent on the preliminary draft 2026 CLFS rate schedules in late September. Furthermore, regaining Medicare coverage for DecisionDx-SCC is still projected to be approximately a year after a positive draft LCD, which itself is only anticipated in the second half of 2026.
The company continues to experience adjusted gross margin compression, with Q2 2026 adjusted gross margin at 76.3% compared to 79.5% in Q2 2025. This decline is primarily driven by increased costs for lab supplies, personnel, and lab services, reflecting investments in capacity and higher test volumes. Sustained margin pressure could impact overall profitability and future investment capacity.
DecisionDx-Melanoma experienced moderate sequential volume growth in Q2 2026, below typical seasonality, partly due to the commercial team adapting to support three products. Additionally, management acknowledges that TissueCypher will increasingly face "headwinds of big numbers," implying that converting remaining physicians will require more effort and potentially higher sales and marketing efficiency to maintain current growth rates.
Bull / Bear Case
- Bear Case
- Despite a favorable crosswalk rate for AdvanceAD-Tx, final reimbursement clarity from commercial payers is contingent on the preliminary draft 2026 CLFS rate schedules in late September. Regaining Medicare coverage for DecisionDx-SCC is still projected to be approximately a year after a positive draft LCD, which itself is only anticipated in the second half of 2026, creating ongoing uncertainty. The company continues to experience adjusted gross margin compression, with Q2 2026 adjusted gross margin at 76.3% compared to 79.5% in Q2 2025, driven by increased costs for lab supplies, personnel, and lab services. DecisionDx-Melanoma experienced moderate sequential volume growth in Q2 2026, below typical seasonality, and management acknowledges that TissueCypher will increasingly face 'headwinds of big numbers,' implying that converting remaining physicians will require more effort.
- Bull Case
- Castle Biosciences delivered exceptional Q2 2026 financial results, with total revenue growing 20% year-over-year to $103.5 million, and core revenue drivers (excluding DecisionDx-SCC and IDgenetix) surging 40%. This strong performance, particularly TissueCypher's 63% volume growth, led to a raised 2026 revenue guidance of $365 million to $375 million, signaling robust market penetration and execution. The AdvanceAD-Tx test for atopic dermatitis is gaining significant traction, with over 1,000 orders in Q2 2026 and a strong reimbursement benchmark of $3,675. The company demonstrates a clear path to profitability, expecting positive adjusted EBITDA for Q3, Q4, and the full year 2026, as well as for 2027, supported by a robust balance sheet of $266.8 million in cash and marketable securities.
- More Compelling & Why
- Bull. Castle Biosciences' current Price-to-Sales (P/S) ratio of approximately 2.34 is significantly below its historical median of around 4.6x and the Diagnostics & Research industry average of ~5x. The strongest argument for the bull case is the robust revenue growth, particularly from TissueCypher and the promising early traction of AdvanceAD-Tx, coupled with the clear path to positive adjusted EBITDA in the second half of 2026 and full year 2027. This indicates the market is valuing the strong top-line expansion and anticipated profitability. My view would flip to bear if the company fails to achieve positive adjusted EBITDA in the forecasted periods or if the growth rates for TissueCypher and AdvanceAD-Tx significantly decelerate.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| DecisionDx-SCC Draft Local Coverage Determination (LCD) Publication by MolDx or Novitas | A favorable draft LCD is crucial for regaining Medicare coverage for DecisionDx-SCC, which would significantly improve market access, test volumes, and revenue contribution for this specialized test. | Publication of a draft LCD by MolDx or Novitas in the second half of 2026, specifically examining the coverage criteria and patient population included. | Publication of a favorable draft LCD with broad coverage criteria in H2 2026 = bullish; Significant delays beyond H2 2026 or restrictive coverage criteria = bearish. | Medicare Administrative Contractor (MAC) websites (e.g., Novitas Solutions, MolDX), company press releases, and investor conference calls. | CMS.gov: LCD search, industry news sites covering Medicare policy changes. | N/A |
| 2026 Total Revenue Guidance Update | Upward revisions to revenue guidance signal strong operational performance, increasing market penetration, and management's confidence in future growth, directly impacting investor sentiment and valuation. | Any further revisions to the 2026 total revenue guidance range, currently $365 million to $375 million. | Upward revision above $375 million = bullish; Downward revision below $365 million = bearish. | Company earnings releases, SEC filings (e.g., 8-K, 10-Q), and investor conference calls. | Financial news outlets (e.g., Reuters, Bloomberg), investor relations section of the company website. | Bloomberg Terminal: CSTL Consensus Estimates, FactSet: CSTL Revenue Forecasts |
| TissueCypher Test Report Volume Growth | TissueCypher is a high-growth segment and a key driver for the company's expansion into gastroenterology. Consistent strong year-over-year growth in test reports is crucial for the overall growth story and market penetration. | Quarterly TissueCypher test report volumes and year-over-year growth rates. Management projects 50% to 52% year-over-year growth for the full year 2026. | Quarterly year-over-year growth rates for TissueCypher test reports consistently at or above 50% = bullish; Growth rates significantly decelerating below 50% year-over-year = bearish. | Company earnings releases, SEC filings (e.g., 10-Q), and investor conference calls. | Industry reports on gastroenterology diagnostics, Google Trends: "TissueCypher test" search volume. | Earnest Analytics: Diagnostic device sales data for TissueCypher, Thinknum: Sales representative job postings for gastroenterology division. |
| Achievement of Positive Adjusted EBITDA for Q3 and Q4 2026 | Consistently achieving positive adjusted EBITDA demonstrates improving profitability and financial discipline, validating the company's growth investments and strengthening its financial health and investor confidence. | Reported Adjusted EBITDA for Q3 2026 and Q4 2026, and the full year 2026. Management expects positive adjusted EBITDA for these periods. | Reported positive Adjusted EBITDA for Q3 2026 and Q4 2026 = bullish; Failure to achieve positive Adjusted EBITDA in these periods = bearish. | Company earnings releases, SEC filings (e.g., 10-Q, 10-K), and investor conference calls. | Financial news outlets, investor relations section of the company website. | Bloomberg Terminal: CSTL Consensus Estimates for EBITDA, FactSet: CSTL EBITDA Forecasts |
| AdvanceAD-Tx Preliminary Draft 2026 CLFS Rate Schedule Publication | The official reimbursement rate and coverage decisions are critical for the commercial expansion and revenue contribution of the newly launched AdvanceAD-Tx test, impacting its market uptake and profitability. | Publication of the preliminary draft 2026 Clinical Laboratory Fee Schedule (CLFS) rate schedules in late September 2026, specifically the affirmed rate for AdvanceAD-Tx. | Affirmation of the $3,675 rate or higher = bullish; A significantly lower rate or unexpected delays in publication = bearish. | CMS website (Medicare.gov) for CLFS updates, company press releases, and investor conference calls. | CMS.gov: Clinical Laboratory Fee Schedule updates, industry news sites covering Medicare reimbursement. | N/A |
Key Reported Metrics, Reratings Triggers & ResultsReimbursement clarity for AdvanceAD-Tx is a critical catalyst for this emerging product. Favorable coverage decisions and a strong rate will unlock significant
Upcoming print · 2026-11-02
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| AdvanceAD-Tx Reimbursement Clarity | N/A | Reimbursement clarity for AdvanceAD-Tx is a critical catalyst for this emerging product. Favorable coverage decisions and a strong rate will unlock significant commercial expansion and future revenue contributions, driving market adoption. |
| TissueCypher Test Reports Growth | 63% | TissueCypher is a high-growth segment and a key driver for the company's expansion into gastroenterology. Sustained strong year-over-year growth in test reports is crucial for the overall growth story and market penetration. |
| Total Revenue | 20% | Total Revenue is a primary indicator of overall business health and market penetration. The company raised its full-year guidance, making continued strong performance crucial for investor confidence and validating its growth strategy. |
Key QuestionsCan Castle Biosciences achieve its raised 2026 total revenue guidance of $365 million to $375 million, particularly given the moderate sequential growth of Deci
Can Castle Biosciences achieve its raised 2026 total revenue guidance of $365 million to $375 million, particularly given the moderate sequential growth of DecisionDx-Melanoma and the sustainability of TissueCypher's high growth?
- Question 2
Will the preliminary draft 2026 CLFS rate schedules in late September affirm the strong $3,675 rate for AdvanceAD-Tx, and how quickly will this translate into broad commercial payer coverage and a full commercial launch to drive significant revenue in 2027 and 2028?
- Question 3
Will Novitas and MolDx release a favorable draft Local Coverage Determination (LCD) for DecisionDx-SCC in the second half of 2026, and will its terms be broad enough to significantly improve the test's reimbursement and market access for Medicare beneficiaries in approximately a year?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. Strong execution and exceeding financial targets: Management highlighted delivering $103.5 million in revenue, a 20% Y/Y growth (40% excluding DecisionDx-SCC and IDgenetix), and raising the 2026 total revenue guidance to $365 million to $375 million, demonstrating confidence in their operational performance and market momentum. 2. Strategic investments in growth initiatives: The company is focused on investing in commercial resources to drive test adoption, generating clinical evidence for reimbursement and expansion, advancing pipeline opportunities in dermatology and gastroenterology, and increasing laboratory capacity, technology, and personnel to support future growth. 3. Advancing key product lines through clinical evidence and market penetration: Management emphasized the continued generation of substantial evidence for DecisionDx-Melanoma (e.g., outperforming MIA Nomogram) and the strong growth of TissueCypher (63% Y/Y volume growth), while also highlighting the positive early reception and clinical utility study for AdvanceAD-Tx. | Call Takeaway & ToneThe call conveyed a highly positive and confident tone, reflecting Castle Biosciences' strong operational execution and financial performance in Q2 2026. Key takeaways include robust revenue growth driven by core products, a significant upward revision of full-year 2026 revenue guidance, and promising early traction for the new AdvanceAD-Tx test with favorable reimbursement developments. Management emphasized strategic investments in growth, clinical evidence generation, and pipeline advancement, while analysts focused on the sustainability of growth, reimbursement clarity for new products, and the impact of sales force adjustments. Despite some questions on sequential trends and future growth pacing, management provided reassuring responses, reinforcing an optimistic outlook for continued market penetration and long-term value creation. | Prior Quarter'S Y/Y Growth By SegmentTotal test report volumes for core revenue drivers (excluding DecisionDx-SCC and IDgenetix) in Q1 2026: approximately 42% Y/Y growth. DecisionDx-Melanoma test reports in Q1 2026: 16% Y/Y growth. TissueCypher test reports in Q1 2026: 58% Y/Y growth. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. AdvanceAD-Tx reimbursement rate and full commercial launch: Analysts inquired about the rate associated with the crosswalk and updated expectations for a full commercial launch. Management expressed satisfaction with the $3,675 rate, viewing it as a strong benchmark for future commercial payer discussions, and indicated it supports a consistent, plotted launch towards a full rollout after the preliminary draft 2026 CLFS rate schedules in late September. 2. TissueCypher ASP trends and the impact on raised guidance: Analysts asked for more detail on Q2 ASP trends, any one-time factors, and if the $20 million guidance raise was primarily due to improved TissueCypher volume. Management confirmed some ASP pickup due to better experience with expected rates but stated they do not expect a similar stepwise increase in the back half, clarifying that most of the guidance raise is based on continued strong performance of both DecisionDx-Melanoma and TissueCypher volumes. 3. DecisionDx-Melanoma's moderate sequential growth and full-year volume confidence: Analysts noted the moderate sequential growth for DecisionDx-Melanoma, which was below typical seasonality, and questioned confidence in the mid-to-high single-digit full-year volume growth. Management attributed the moderate sequential growth partly to the commercial team adapting its customer engagement model to support three products and reiterated confidence in achieving mid-to-high single-digit volume growth for the full year 2026 based on their internal models. | Revenue SegmentsTotal Revenue: 20% Y/Y growth. Revenue (excluding DecisionDx-SCC and IDgenetix): 40% Y/Y growth. Core Revenue Drivers (test report volume): 32% Y/Y growth. DecisionDx-Melanoma (test reports): 3% Y/Y growth. TissueCypher (test reports): 63% Y/Y growth. AdvanceAD-Tx: Over 1,000 orders in Q2 2026 (Y/Y growth not provided as it is a newer test). DecisionDx-SCC: Volumes picked up (Y/Y growth not specified). |
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. Executing growth priorities and raising 2026 revenue outlook: Management delivered strong Q1 results and raised their 2026 revenue outlook to between $345 million to $355 million, up from the previous guidance of $340 million to $350 million, reflecting confidence in their growth strategy. 2. Driving adoption and competitive advantage for DecisionDx-Melanoma through robust clinical evidence: Management highlighted 16% year-over-year growth in DecisionDx-Melanoma test reports and presented new data demonstrating the test's ability to significantly improve risk prediction within AJCC stages. 3. Expanding the gastroenterology franchise with TissueCypher and its clinical evidence: TissueCypher showed 58% year-over-year growth in test reports, and new studies were presented at Digestive Disease Week demonstrating its utility in refining risk assessment and informing management decisions for Barrett's esophagus patients. | Call Takeaway & ToneThe overall takeaway of the call was positive and confident. Castle Biosciences delivered strong first-quarter results, driven by significant year-over-year growth in its core revenue drivers, DecisionDx-Melanoma and TissueCypher. Management raised the full-year 2026 revenue outlook, signaling confidence in their growth strategy and execution. The early response to the new AdvanceAD-Tx test was also highlighted as very positive. While analysts questioned some sequential trends and future growth phasing, management provided reassuring responses, emphasizing clinical evidence, market penetration, and strategic capacity planning. The tone was optimistic about continued progress and long-term value creation. | Prior Quarter'S Y/Y Growth By SegmentIn Q4 2025, DecisionDx-Melanoma test reports grew 15.56% year-over-year. In Q4 2025, TissueCypher test reports grew 76.90% year-over-year. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. TissueCypher volume decline quarter-over-quarter despite strong Y/Y growth: Management explained that they are now seeing seasonality, with Q1 historically having fewer GI procedures, but noted that March was a record month for TissueCypher and the trend continued in April, expecting year-over-year growth approaching 50% for the full year. 2. Reimbursement initiatives for AdvanceAD-Tx and potential for material revenue: Management stated they expect to provide more detail on reimbursement by the end of Q3 2026, based on traditional reimbursement approaches, and also mentioned other potential avenues like interested parties controlling costs or partnerships with pharmaceutical companies. 3. DecisionDx-Melanoma volume growth expectations for the year (mid-to-high single-digit guidance vs. strong Q1): Management reiterated their mid-to-high single-digit growth expectations for 2026, noting that Q1 had an easier comparable than the rest of the year. | Revenue SegmentsTotal test report volumes for core revenue drivers grew 36% year-over-year. Excluding DecisionDx-SCC and IDgenetix revenue, total revenue growth was approximately 42% year-over-year. DecisionDx-Melanoma test reports grew 16% year-over-year. TissueCypher test reports grew 58% year-over-year. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketCastle Biosciences' AdvanceAD-Tx test, which guides systemic treatment selection for moderate to severe atopic dermatitis patients aged 12 and up, received over 1,000 orders in the second quarter. A new independent real-world clinical utility study for AdvanceAD-Tx showed that while only 54.3% of patients were initially on pathway concordant treatment, 97.8% were initiated on molecularly concordant systemic therapy following testing. The company believes the crosswalk code for AdvanceAD-Tx, with a rate of $3,675, is strong and will serve as a benchmark for commercial payers. For TissueCypher, the company notes significant runway ahead as many physicians have not yet been educated on its clinical benefits for Barrett's esophagus patients. The DETECT-AD study with SciBase aims to help patients understand and control their disease, potentially allowing them to use less high-powered topical therapies, taper off rescue medications quicker, or lengthen out injection rates for systemic therapies. | About CompetitionRegarding DecisionDx-Melanoma, the company has not seen significant changes in the competitive environment in recent months, with promotional responsiveness and the value of their test remaining consistent. | About The Broader IndustryThe company observes seasonality in the gastroenterology market, with fewer GI procedures historically in the first quarter, similar to trends seen on the dermatology side. Clinicians are actively seeking tools, such as the AdvanceAD-Tx test, to aid in making more informed and better therapy selections aligned with individual patient's underlying disease biology. There is a broader market trend where patients desire to lengthen out their injection rates or use of oral therapies to reduce medication frequency, which the company's device aims to support. The company does not have visibility into potential impacts from ACA disenrollment on test volumes or shifts towards self-pay. | Where Things Are HeadedCastle Biosciences raised its 2026 total revenue guidance to $365 million to $375 million, up from $345 million to $355 million, reflecting confidence in continued positive momentum. The company expects to achieve positive adjusted EBITDA for the third quarter, fourth quarter, and full year 2026, and for the full year 2027. For TissueCypher, 2026 test report volume is projected to trend toward 50% to 52% growth compared to 2025. DecisionDx-Melanoma is on track for mid- to high single-digit volume growth for the full year 2026. The company anticipates preliminary draft 2026 CLFS rate schedules for AdvanceAD-Tx in late September, which will help set reimbursement rates with commercial payers for a full launch in the future. For DecisionDx-SCC, if a positive draft coverage LCD is released by Medicare contractors in the second half of 2026, the company anticipates regaining coverage for Medicare beneficiaries approximately a year later. FDA clearance or approval for a breakthrough device is expected later this year or early next year. An update on the Previse GI pipeline test is anticipated in the first half of next year. | Updates On ThemeCastle | Bullish-Leaning Quotes (Short)What a great quarter. We delivered revenue of $103.5 million, 20% growth compared to the second quarter of 2025. Test report volume for our core revenue drivers grew 32%. We delivered 14,988 TissueCypher test reports, representing 63% growth. We were particularly pleased that the AdvanceAD-Tx was recently recognized with the Genomics Innovation Award. Following testing with our AdvanceAD-Tx, 97.8% of patients were initiated on molecularly concordant systemic therapy. The rate of [ $3,675 ], I think, is a very, very strong rate for our test. We are quite pleased with the panel's recommendation. We expect to achieve positive adjusted EBITDA for the third quarter, the fourth quarter and the full year 2026. Our strong balance sheet continues to provide financial flexibility to invest in our growth priorities. I'm encouraged by the momentum we're carrying into the remainder of the year. | Bearish-Leaning Quotes (Short)DecisionDx-Melanoma test volume also increased approximately 3% in the second quarter of 2026 compared with the first quarter of 2026, representing moderate sequential growth, though below the sequential increase we typically see. This moderate sequential growth was due in part to our commercial team adapting its customer engagement model to support 3 products within the same customer call. Our gross margin during the second quarter of 2026 was 74.9% compared to 77.3% in the second quarter of 2025. Our adjusted gross margin... was 76.3% for the quarter compared to 79.5% for the same period in 2025. I wouldn't expect to see the same stepwise increase in the back half [for TissueCypher ASP]. We are certainly going to begin to face the headwinds of big numbers. And by definition, the easier physicians to convert are the first ones and the ones that come later are perhaps take a bit more work. | HiringThe company continues to add laboratory capacity, technology, and personnel to support future growth. Sales and marketing expenses increased primarily due to higher personnel costs. General and administrative expenses rose, primarily attributable to higher personnel costs reflecting headcount expansions in administrative functions and annual wage adjustments. Cost of sales expenses increased due to higher personnel costs, reflecting a higher headcount to support business growth and growing test report volumes, as well as wage adjustments. R&D expenses increased primarily due to higher personnel costs driven by increased headcount to support continued business growth. The company is 'kind of floating around 100 sales representative sales territories for both our gastroenterology division and our dermatology division' and had expansions late in the second quarter. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketCastle Biosciences' AdvanceAD-Tx test, designed to guide systemic treatment selection for moderate-to-severe atopic dermatitis patients, received approximately 650 orders in Q1 2026 under a limited access program. The company expects to add a similar number of TissueCypher tests in 2026 as in 2025, indicating year-over-year growth approaching 50%. DecisionDx-Melanoma data presented at the 2026 American Academy of Dermatology Annual Meeting demonstrated the test's ability to significantly improve risk prediction within AJCC stages, identifying patients with substantially higher or lower mortality risk than staging alone would predict. The company also stated that M&A is expected to play a role in its growth story, with continued evaluation of candidates that fit its strategic opportunities criteria. | About CompetitionThe company aims to sustain its competitive advantage for DecisionDx-Melanoma through robust clinical evidence. Feedback from clinicians regarding NCCN guidelines suggests a perception that the guidelines are 'more political than we even thought' concerning a study that 'failed to meet the 5% cut point'. | About The Broader IndustryThe gastroenterology market experiences seasonality, with historically fewer GI procedures in the first quarter of the year. The company noted that long revenue cycles from a revenue cycle management (RCM) perspective are a factor for new test reimbursement. M&A is recognized as a potential growth strategy within the industry. | Where Things Are HeadedCastle Biosciences raised its 2026 revenue outlook to between $345 million and $355 million, up from the previously provided range of $340 million to $350 million. The company expects DecisionDx-Melanoma to achieve mid- to high single-digit volume growth for the full year 2026. TissueCypher is anticipated to add a similar number of test reports in 2026 as in 2025, indicating year-over-year growth approaching 50%. The AdvanceAD-Tx test is viewed as a midterm (2027 and 2028) revenue driver, with more detail on reimbursement expected by the end of the third quarter 2026. The company is moving forward with an FDA submission for melanoma in 2026. A draft LCD for DecisionDx-SCC is anticipated in the second half of 2026, following accepted reconsideration requests. M&A is expected to play a role in the company's future growth. | Updates On ThemeThe | Bullish-Leaning Quotes (Short)We delivered strong first quarter results, building on our momentum from 2025. Test report volumes for our core revenue drivers grew 36% compared to the first quarter of 2025. raising our 2026 revenue outlook to between $345 million to $355 million. March of 2026 saw an all-time high record month for test reports delivered. TissueCypher test reports... which is 58% growth. having 650 orders come in the door in the first quarter is very, very nice reinforcement of the opportunity that we have here. We are quite pleased with the continued early response of the dermatologic clinicians out there in the field. We still continue to believe that there -- that kind of a year plus review cycle should be plenty of time for a reconsideration request... That would be surprising. | Bearish-Leaning Quotes (Short)volumes did decline very modestly quarter-over-quarter. Q1 was a bit of an easier comp than we expect for the rest of the year. I don't quite understand what NCCN sees here. I think, unfortunately, from an NCCN standpoint, there's a belief that this is really more political than we even thought, I guess you would say. the primary hurdle for our AD test is just our -- candidly, our willingness to -- how available do we want to make it. it was a little bit surprising to see the net loss and the lower-than-expected EBITDA in the quarter. | HiringIncreases in personnel costs reflect a higher headcount driven by sales force expansion, headcount expansions in administrative support functions, and additions made to support business growth in response to growing test report volumes. There was also a higher headcount to support continued business growth and increases in clinical studies costs. The company currently covers both dermatology and gastroenterology verticals with fewer than 100 sales representatives. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-07-30 | Castle Biosciences reported strong Q2 2026 results, with revenue of $103.5 million beating estimates and core test volumes up 32%. TissueCypher surged 63% year-over-year, driving a raised full-year 2026 revenue guidance to $365-375 million. The company also anticipates positive Adjusted EBITDA for the rest of 2026. CSTL's stock gained 4.52% post-earnings, significantly outperforming SPY, indicating strong market confidence in its growth trajectory and path to profitability. | Earnings Transcript | Positive | https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG11rM7MtsUyxR7t7XXwk7S5Yn76y4hldM-hcaY3zLm5rjpt4XvRiHTlz8O6-y44Ns1wca8rBa9FqU4p02gTnPpzh2yKbCdIFUis4_hwGqOiLQZa9H_EnZXq6y3rtgjTYj03utpaGqGChW4FrZjwoXW9CS0DgvUbV1IRMUCaZrGx5Ni5NbsFioyDx2RPX53Ywoxnr3uCMCKgwHN | +4.52% (vs SPY: +4.52%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| CSTL_6f281b49 | preliminary draft 2026 CLFS rate schedules in late September | 2026-09-20 | 2026-09-30 | CMS to release preliminary draft 2026 Clinical Laboratory Fee Schedule (CLFS) rate schedules, expected to affirm the crosswalk rate for AdvanceAD-Tx. | This provides a critical benchmark for future commercial payer reimbursement discussions, paving the way for a broader launch of AdvanceAD-Tx. | Ticker | 2026-07-30 | earnings_transcript |